The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections

Abstract

The intra-articular injection of bone marrow-derived mononuclear cells is a safe manipulation with no side effects during the 12-month period. This treatment provides statistically significant clinical improvement between the starting point and 1, 3, 6, and 12 months after. When compared to hyaluronic acid treatment, better pain relief in the long-term period of mononuclear cell group was observed.

Bone marrow mononuclear cells for joint therapy: The role of macrophages in inflammation resolution and tissue repair

“…During the last decade, several reports have demonstrated successful use of BMNC in the treatment of chronic synovitis and joint disease[ 25 , 46 , 55 , 101 - 104 ]. Early studies suggesting BMNC could be an effective therapy for joint disease evaluated its effect on “tennis elbow” (elbow lateral epicondylitis), and found a significant improvement using a standardized patient-rated evaluation.…”

“…Unfortunately, the experimental design did not include an assessment of control groups or a comparative therapy[ 101 ]. More recently, Goncars et al [ 102 ], evaluated the clinical efficacy of a single joint injection with BMNC to improve pain and other symptoms of moderate knee OA [Kellgren-Lawrence (KL) stage II–III] in a cohort of 28 patients that were followed for 12 mo[ 104 ]. The clinical assessments were based on the Knee osteoarthritis outcome score (KOOS) and the Knee society score (KSS) at baseline, 3 mo, 6 mo, and 12 mo after injection, and compared to a patient group ( n = 28) treated with 3 consecutive weekly injections of sodium hyaluronate[ 104 ].…”

“…More recently, Goncars et al [ 102 ], evaluated the clinical efficacy of a single joint injection with BMNC to improve pain and other symptoms of moderate knee OA [Kellgren-Lawrence (KL) stage II–III] in a cohort of 28 patients that were followed for 12 mo[ 104 ]. The clinical assessments were based on the Knee osteoarthritis outcome score (KOOS) and the Knee society score (KSS) at baseline, 3 mo, 6 mo, and 12 mo after injection, and compared to a patient group ( n = 28) treated with 3 consecutive weekly injections of sodium hyaluronate[ 104 ]. Significant improvement ( P < 0.05) was observed in the BMNC-treated group for all scores at all time points, with special superiority in the KOOS pain subscale for BMNC over the hyaluronic acid-treated group at 6 and 12 mo.…”

Safety and Effectiveness of Intraarticular Administration of Adipose-Derived Stromal Vascular Fraction for Treatment of Knee Articular Cartilage Degenerative Damage: Preliminary Results of a Clinical Trial

“…Например, в одной из работ показана большая эффективность обо-гащенной тромбоцитами плазмы по сравнению с гиалуроновой кислотой при их внутрисустав-ном введении по показателям боли в колен-ном суставе, оцененной по шкале ВАШ и сум-ме баллов по шкале IKDC (International Knee Documentation Committee score) [25]. В другом исследовании показана более высокая эффек-тивность внутрисуставного введения монону-клеаров костного мозга по сравнению с гиалу-роновой кислотой [26]. Вместе с тем, сведений о сравнительных исследованиях эффективно-сти применения СВФ и других клеточных про-дуктов при ОА в доступной литературе нет.…”

“…AP and lateral x-ray of the knee joint after completion of the study обсуждение В настоящее время для лечения ОА колен-ного сустава в распоряжении клиницистов имеется широкий набор методов с доказанной эффективностью, таких как внутрисуставные инъекции гиалуроновой кислоты и глюкокорти-коидов. Однако отдаленные результаты приме-нения этих методов сложно признать удовлетво-рительными, что обуславливает необходимость разработки новых способов лечения [10,25,26].…”